Standardized Representation, Visualization and Searchable Repository of Antiretroviral Treatment-change Episodes

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2012 May 5

PMID 22554313

Citations 2

Authors

Soo-Yon Rhee

Jose Luis Blanco

Tommy F Liu

Inaki Pere

Rolf Kaiser

Maurizio Zazzi

Francesca Incardona

William Towner

Josep Maria Gatell

Andrea De Luca

W Jeffrey Fessel

Robert W Shafer

Affiliations

Soon will be listed here.

Abstract

Background: To identify the determinants of successful antiretroviral (ARV) therapy, researchers study the virological responses to treatment-change episodes (TCEs) accompanied by baseline plasma HIV-1 RNA levels, CD4+ T lymphocyte counts, and genotypic resistance data. Such studies, however, often differ in their inclusion and virological response criteria making direct comparisons of study results problematic. Moreover, the absence of a standard method for representing the data comprising a TCE makes it difficult to apply uniform criteria in the analysis of published studies of TCEs.

Results: To facilitate data sharing for TCE analyses, we developed an XML (Extensible Markup Language) Schema that represents the temporal relationship between plasma HIV-1 RNA levels, CD4 counts and genotypic drug resistance data surrounding an ARV treatment change. To demonstrate the adaptability of the TCE XML Schema to different clinical environments, we collaborate with four clinics to create a public repository of about 1,500 TCEs. Despite the nascent state of this TCE XML Repository, we were able to perform an analysis that generated a novel hypothesis pertaining to the optimal use of second-line therapies in resource-limited settings. We also developed an online program (TCE Finder) for searching the TCE XML Repository and another program (TCE Viewer) for generating a graphical depiction of a TCE from a TCE XML Schema document.

Conclusions: The TCE Suite of applications - the XML Schema, Viewer, Finder, and Repository - addresses several major needs in the analysis of the predictors of virological response to ARV therapy. The TCE XML Schema and Viewer facilitate sharing data comprising a TCE. The TCE Repository, the only publicly available collection of TCEs, and the TCE Finder can be used for testing the predictive value of genotypic resistance interpretation systems and potentially for generating and testing novel hypotheses pertaining to the optimal use of salvage ARV therapy.

Citing Articles

Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool.

Pironti A, Pfeifer N, Walter H, Jensen B, Zazzi M, Gomes P PLoS One. 2017; 12(4):e0174992.

PMID: 28394945 PMC: 5386274. DOI: 10.1371/journal.pone.0174992.

Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data.

Pironti A, Walter H, Pfeifer N, Knops E, Lubke N, Buch J J Acquir Immune Defic Syndr. 2016; 74(5):e129-e137.

PMID: 27787339 PMC: 5351752. DOI: 10.1097/QAI.0000000000001198.

References

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

King M, Rode R, Cohen-Codar I, Calvez V, Marcelin A, Hanna G . Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007; 51(9):3067-74. PMC: 2043245. DOI: 10.1128/AAC.00388-07. View

De Luca A, Di Giambenedetto S, Trotta M, Colafigli M, Prosperi M, Ruiz L . Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. J Infect Dis. 2007; 196(11):1645-53. DOI: 10.1086/522231. View

Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M . Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010; 24(4):503-14. DOI: 10.1097/QAD.0b013e32833677ac. View

Masquelier B, Assoumou K, Descamps D, Bocket L, Cottalorda J, Ruffault A . Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J Antimicrob Chemother. 2008; 61(6):1362-8. DOI: 10.1093/jac/dkn127. View

. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection. HIV Clin Trials. 2001; 1(1):60-110. DOI: 10.1310/hct.2000.1.1.008. View

Prosperi M, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A . A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak. 2011; 11:40. PMC: 3144446. DOI: 10.1186/1472-6947-11-40. View

Larder B, Wang D, Revell A, Montaner J, Harrigan R, de Wolf F . The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther. 2007; 12(1):15-24. View

Loutfy M, Raboud J, Walmsley S, Saskin R, Montaner J, Hogg R . Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther. 2004; 9(4):595-602. View

10.

Lanier E, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G . Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004; 9(1):37-45. DOI: 10.1177/135965350400900102. View

11.

Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B . Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010; 11(8):510-8. PMC: 4833877. DOI: 10.1111/j.1468-1293.2010.00825.x. View

12.

Rhee S, Fessel W, Liu T, Marlowe N, Rowland C, Rode R . Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis. 2009; 200(3):453-63. PMC: 4774893. DOI: 10.1086/600073. View

13.

De Luca A, Cingolani A, Di Giambenedetto S, Trotta M, Baldini F, Rizzo M . Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis. 2003; 187(12):1934-43. DOI: 10.1086/375355. View

14.

Howe H, Lake A, Shen T . Method to assess identifiability in electronic data files. Am J Epidemiol. 2006; 165(5):597-601. DOI: 10.1093/aje/kwk049. View

15.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A . Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. Antivir Ther. 2011; 16(4):489-97. DOI: 10.3851/IMP1799. View

16.

Brun-Vezinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G . Clinically relevant interpretation of genotype for resistance to abacavir. AIDS. 2003; 17(12):1795-802. DOI: 10.1097/00002030-200308150-00008. View

17.

Kjaer J, Ledergerber B . HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther. 2004; 9(4):631-3. View

18.

Molina J, Marcelin A, Pavie J, Heripret L, Merle De Boever C, Troccaz M . Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005; 191(6):840-7. DOI: 10.1086/428094. View

19.

Masquelier B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L . Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther. 2004; 9(3):315-23. View

20.

Grant P, Wong E, Rode R, Shafer R, De Luca A, Nadler J . Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Antimicrob Agents Chemother. 2008; 52(11):4050-6. PMC: 2573134. DOI: 10.1128/AAC.00605-08. View